KNSA · Kiniksa Pharmaceuticals International, plc · Executive Compensation
$93.90
+0.36 (+0.38%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.38B
Shares
78.57M
Volume · Nov 20
545.23K
Avg daily vol (3M)
658.72K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ross Moat | President and Chief Operating Officer | Appointed | 2026-10-22 |
|
Eben Tessari
“Mr. Tessari’s decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.”
|
Chief Strategy Officer | Resigned | 2026-05-01 |
| Eben Tessari | Chief Strategy Officer | Appointed | 2026-01-14 |
| Ross Moat | Chief Operating Officer and principal operating officer | Appointed | 2026-01-14 |
| M. Cantey Boyd | member of the Class III directors | Appointed | 2024-10-07 |
| Eben Tessari | SVP, Chief Operating Officer | Appointed | 2022-01-03 |
| Madelyn Zeylikman | General Counsel | Appointed | 2021-05-12 |
| Mark Ragosa | VP, Interim Chief Financial Officer | Appointed | 2020-12-22 |
Leadership
- Sanj K. Patel CEO, Board Member
- Mark Ragosa CFO
- Ross Moat COO
- Madelyn Zeylikman General Counsel
- Michael Megna Chief Accounting Officer
- Barry D. Quart Board Member
- Felix J. Baker Board Member
- G. Bradley Cole Board Member
- Kimberly J. Popovits Board Member
- M. Cantey Boyd Board Member
- Richard S. Levy Board Member
- Stephen R. Biggar Board Member
- Thomas R. Malley Board Member
- Tracey L. McCain Board Member
Key facts
CIK
1730430
CUSIP
G52694109
13F (30d)
280 filings
272 filers
Visit website
Investor relations